Trial intelligence / Profile preview

JIM Study of adolescent booster meningococcal vaccination

NL-OMON38656Not yet recruiting

Sponsor
National Institute for Public Health and the Environment
Start
Mar 2014
Modality
Vaccines & Immunotherapeutics
Countries
1
01

Overview

Open-label trial of Meningococcal polysaccharide vaccine group W-135 and Meningococcal group C polysaccharide conjugate vaccine in meningococcal disease (6 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoints: MenC SBA non-inferiority at 1 year and MenA, MenW, and MenY SBA comparison by age group. Planned start Mar 2014; status: not yet recruiting.

02

Drugs

Meningococcal polysaccharide vaccine group W-135Meningococcal group C polysaccharide conjugate vaccine
03

Conditions

meningococcal disease

Beyond the preview

Go deeper on NL-OMON38656.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON38656.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call